Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have been diagnosed (clinically) with T2D, based on the World Health Organization (WHO) classification for at least 1 year prior to screening.~* Have been treated for at least 90 days prior to screening with:~  * Basal insulin (insulin glargine U-100 \[Basaglar/Abasaglar or LANTUS\] or U-300, insulin detemir, insulin degludec U-100 or U-200, or neutral protamine Hagedorn \[NPH\] insulin) in combination with at least 1 prandial injection of bolus insulin (insulin lispro U-100 or U-200, insulin aspart, insulin glulisine, or regular insulin) Or~ * Premixed analog or human insulin regimens with any basal and bolus insulin combination injected at least twice daily~* Participants may be treated with up to 3 of the following oral antihyperglycemic medications (OAMs) in accordance with local regulations:~  * Metformin~ * Dipeptidyl peptidase-4 (DPP-4) inhibitor~ * Sodium glucose cotransporter 2 (SGLT2) inhibitor~ * Sulfonylurea~ * Meglitinide~ * Alpha-glucoside inhibitor~* Have an HbA1c value between ≥7.0 and ≤10.0%, according to the central laboratory at the time of screening.~* Have a body mass index (BMI) of ≤45.0 kilograms per meter squared at screening.~Exclusion Criteria:~* Have been diagnosed, at any time, with type 1 diabetes (T1D) or Latent Autoimmune Diabetes in Adults.~* Have hypoglycemia unawareness as judged by the investigator.~* Have had any episode of severe hypoglycemia within the 6 months prior to screening.~* Have had 1 or more episodes of diabetic ketoacidosis or hyperglycemic hyperosmolar state within the 6 months prior to screening.~* Have used thiazolidinediones, Glucagon-Like Peptide 1 (GLP-1) receptor agonist, or pramlintide within 90 days prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY900014 (Type: EXPERIMENTAL): LY900014 given subcutaneously (SC) with each meal with either 100 U/mL (U-100) basal insulin glargine given SC once or twice daily or U-100 or 200 U/mL (U-200) insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
- Insulin Lispro (Humalog) (Type: ACTIVE_COMPARATOR): Insulin lispro given SC with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
- LY900014 Maximum Extended Enrollment (MEE) (Type: EXPERIMENTAL): LY900014 given subcutaneously (SC) with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
- Insulin Lispro (Humalog) MEE (Type: ACTIVE_COMPARATOR): Insulin lispro given SC with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.

Based on this trial design, predict the completion outcome and termination type (if applicable).